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Abstract 
The therapeutic activity of a wide variety of drugs is significantly improved when their longevity in the circulation is extended by 
encapsulation in liposomes. To improve the retention of cationic drugs in liposomes, we have investigated the effect of the cationic lipid 
stearylamine onthe permeability of the calcium channel blocker verapamil and the antipsychotic drug prochlorperazine, both of which are 
also multidrug resistance modulators. Both drugs were efficiently incorporated into liposomes composed of DSPC/cholesterol that 
possessed a transmembrane pH gradient (inside acidic). However, the efflux of the loaded drugs was relatively rapid (i.e., 50% of the 
encapsulated verapamil was released after 4 h at 37°C), despite the presence of a 3 unit pH gradient (pH i = 4.0, pHo = 7.5). Drug 
retention within the liposomes was improved by increasing the magnitude of the transmembrane pH gradient o approx. 5 units 
(pH i = 2.0, pH o = 7.5). Further improvements in drug retention were achieved by the addition of 10 mol% of the cationic lipid 
stearylamine in the DSPC/cholesterol liposomes. The combination of the 5 unit pH gradient and stearylamine r sulted in increases of the 
retention of verapamil and prochlorperazine by approx. 20- and 5-fold, respectively. Calculation of the permeability coefficients for the 
charged (cationic) and neutral forms of the drugs indicated that the neutral forms of both drugs were approx. 104-fold more permeable 
than were the cationic forms of the drugs. Further, the presence of stearylamine r duced the permeability coefficient for the cationic 
species of the drugs by approximately an order of magnitude, but had no effect on the neutral species of the drugs. The efflux curves 
observed for both verapamil and prochlorperazine could be mathematically modeled by assuming that the primary influence of 
stearylamine was on the development of a positive surface charge density on the inner monolayer of the liposome. Taken in sum, these 
results indicate that stearylamine is effective at decreasing the leakage of cationic drugs from liposomes, and may prove to be a valuable 
component of liposomal drug formulations. 
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1. Introduction 
The clinical usefulness of a number of drugs is fre- 
quently limited by the occurrence of deleterious ide ef- 
fects at concentrations similar to, or lower than, those 
required for maximum therapeutic activity. The utility of 
such compounds may be significantly enhanced, and their 
toxic activities significantly reduced, by encapsulation 
within delivery systems such as liposomes. For example, 
Abbreviations: DPPC, dipalmitoylphosphatidylcholine; DSPC, dis- 
tearoylphosphatidylcholine. 
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encapsulation of the anticancer agents doxorubicin and 
vincristine within liposomes reduces the toxicities of these 
compounds and improves their antitumor efficacy [1-3]. It 
is likely that the therapeutic activity of liposome-encapsu- 
lated agents is due, in part, to accumulation of the carrier 
and encapsulated drug at the disease site [4]. Therefore, 
effective delivery of therapeutic drugs to selected tissues 
requires that the delivery vehicle does not allow significant 
leakage of the drug prior to its accumulation at the target 
site. Consequently, our optimization studies have focused 
on the development of l iposomes possessing enhanced 
drug retention characteristics. Specifically, we have at- 
tempted to improve drug retention by determining some of 
the factors that influence the permeability of lipid bilayers 
to amphipathic amines. 
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An example of a drug successfully encapsulated into 
well-characterized liposomal systems is the anticancer 
agent doxorubicin [5]. After uptake of doxorubicin into 
liposomes in response to a transmembrane pH gradient, he 
leakage of intraliposomal doxorubicin is very slow [6]. It is 
possible that the slow leakage of encapsulated doxorubicin 
is a consequence of both the partitioning of entrapped 
doxorubicin into the inner monolayer of the liposomal 
membrane [5] and the formation of intraliposomal ggre- 
gates [7]. However, other therapeutic compounds, uch as 
vincristine, may not partition into the membrane or readily 
precipitate in the intraliposomal space and, therefore, are 
less likely to be as effectively retained within comparable 
liposomal systems. Indeed, a survey of a variety of drugs 
loaded by the transmembrane pH gradient method indi- 
cated that many compounds (including vincristine, vinblas- 
tine, quinidine, diphenhydramine, quinine and chloroquine) 
leak from liposomes during extended periods [8]. There- 
fore, it is likely that the low liposomal leakage observed 
for doxorubicin is an exception, and that rapid leakage of 
encapsulated drugs will pose a significant technical obsta- 
cle to the development of many liposomal drug formula- 
tions. 
Many of the compounds possessing therapeutic activity 
are lipophilic or amphipathic amines. This class of com- 
pounds are weak bases and, therefore, can be trapped 
inside unilamellar liposomes by imposing a transmem- 
brane pH gradient (inside acidic) such that the agents 
redistribute across the bilayer until the internal/external 
concentration gradient approximates the proton gradient. 
Previous studies have demonstrated that a decrease of the 
intraliposomal pH below 4.0 can increase the retention of 
these drugs [9]. We speculated that the leakage of encapsu- 
lated cationic drugs could be further educed or precluded 
if the inner monolayer of the liposomes possessed a posi- 
tive surface charge that would reduce cationic drug parti- 
tioning into the bilayer via electrostatic repulsion. It has 
been previously established that stearylamine quantita- 
tively redistributes to the inner monolayer of a liposome in 
response to a transmembrane pH gradient, inside-acidic 
[10,11]. Therefore, in the present study we have utilized 
stearylamine to generate liposomes possessing a positive 
surface charge located on the inner monolayer. 
This paper describes experiments examining the perme- 
ability of large unilamellar liposomes composed of dis- 
tearoylphosphatidylcholine (DSPC) and cholesterol to the 
cationic drugs verapamil and prochlorperazine, and evalu- 
ates the relative contributions of the intraliposomal pH and 
surface charge on drug retention. Verapamil is an effective 
calcium channel blocker while prochlorperazine is used as 
an antipsychotic and neuroleptic agent. Both verapamil and 
prochlorperazine possess titratable tertiary amine functions 
(Fig. 1) and were expected to be readily encapsulated into 
liposomes possessing a transmembrane pH gradient. Vera- 
pamil and prochlorperazine were also of interest due to 
their ability to inhibit the activity of plasma membrane 
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Fig. 1. Chemical structures of verapamil and prochlorperazine. 
P-glycoprotein which is responsible for acquired and inher- 
ent resistance of some tumors to anticancer drugs such as 
doxorubicin and vincristine [12]. However, verapamil 
achieves up to 100% inhibition, in vitro, of P-glycoprotein 
at concentrations i  the range of 2-10/zM but has serious 
cardiovascular side-effects, in vivo, at approx. 6 /zM [12]. 
Therefore, the development of liposomal formulations of 
verapamil and prochlorperazine is expected to have signifi- 
cant therapeutic benefit in the treatment of tumors that are 
resistant to chemotherapy. 
2. Materials and methods 
2.1. Materials 
Distearoylphosphatidylcholine (DSPC) was obtained 
from Avanti Polar Lipids. Verapamil (hydrochloride), 
prochlorperazine ( disylate salt) and all other chemicals 
were obtained from Sigma. N-[ methyl- 3H]Verapamil, di[ 1- 
14C]palmitoylphosphatidylcholine, [4-14C]cholesteryl hex- 
adecyl ether and [4-3H]cholesteryl hexadecyl ether were 
obtained from New England Nuclear. [~4C]Methylamine 
was obtained from Amersham. 
2.2. Liposome preparation 
Dry lipids were weighed, dissolved in CHC! 3, and 
mixed in the molar ratios of DSPC/cholesterol (55:45) or 
DSPC/cholesterol/stearylamine (50:40:10). Typical 
preparations consisted of 100 mg of lipid and 0.5-1.0 /xCi 
of either [14C]DPPC, [3H]cholesteryl hexadecyl ether or 
[14C]cholesteryl hexadecyl ether. Excess solvent was re- 
moved under a stream of N e gas, then trace solvent 
removed by holding the lipid film under high vacuum for 
3-16 h. 
Lipids were dispersed by the addition of 1.0 ml of 0.3 
M citrate buffer at either pH 2.0 or 4.0 and were then 
heated to 60°C, vortexed extensively, and subjected to five 
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freeze/thaw cycles between - 196 ° and 60°C to facilitate 
homogeneous solute and buffer distribution between the 
intra- and extra-liposomal compartments [13]. After the 
final freeze/thaw cycle, the multilamellar vesicles were 
converted to large unilamellar vesicles by repeated extru- 
sion through two 0.1 /zm filters employing a Thermobarrel 
Extruder at 65°C (Lipex Biomembranes, Vancouver, BC). 
Vesicle size distribution was determined by quasielastic 
light scattering (QELS) using a Nicomp 370 Particle Sizer; 
all liposome preparations had mean diameters in the range 
between 125 and 135 nm. 
2.3. Measurement of transmembrane pH gradient 
Large unilamellar liposomes of either DSPC/cholesterol 
or DSPC/cholesterol/stearylamine co taining 1.0 /zCi of 
[3H]cholesteryl hexadecyl ether were prepared at pH 4.0 or 
2.0 as described above. Aliquots of 10 mg of lipid were 
alkalinized by the addition of 0.5 M Na2HPO 4 then the 
lipid concentration was brought to 2.0 mg/ml by the 
addition of 150 mM NaC1, 20 mM Hepes (pH 7.5, HBS). 
Liposomes were equilibrated at 60°C for l0 min then 1 
/xCi of [J4C]methylamine was added (in 1 /xl ethanol) and 
the probe was allowed to redistribute for an additional 10 
min at 60°C. After cooling to room temperature, the 
liposomes and encapsulated [ UC]methylamine were recov- 
ered by centrifugation of 1 ml aliquots of the suspension 
on micropartition concentrators (Amicon Centrifree or 
Amicon Microcon-30) for 10 min at 2000×g,  4°C. 
Aliquots of the suspensions taken before and after centrif- 
ugation were assayed by LSC to calculate the inside/out- 
side ratio of [HC]methylamine and, consequently, the 
transmembrane pH gradient. 
2.4. Drug uptake and leakage 
Verapamil and prochlorperazine were loaded into lipo- 
somes in response to a transmembrane pH gradient. For 
liposomes in 0,3 M citrate buffer at pH 4.0, the external 
medium was alkalinized by the addition of a small volume 
of 0.5 M Na2CO 3 (65 /xl/100 /~l liposomes). Similarly, 
liposomes in 0.3 M citrate buffer at pH 2.0 were alkalin- 
ized by the addition of 85 /zl of 0.5 M Na2CO 3 per 100 
p.l of liposomes. The final pH outside of the liposomes 
using this method was 7.3-7.6. 
Uptake of either verapamil (containing 0.1 /xCi 
[3H]verapamil/mg verapamil) or prochlorperazine was ini- 
tiated by the addition of 2 mg of drug in 200 /zl of 150 
mM NaC1 or HBS, respectively, to 10 mg of liposomes at 
12.5 mg lipid/ml. The drug/lipid ratio of 0.2:1 (w/w) for 
verapamil (hydrocbloride salt) and prochlorperazine 
(edisylate salt) represents free drug/lipid (mol/mol) ratios 
of 0.185 and 0.133, respectively. Uptake was allowed to 
proceed for 10 rain at temperatures of 21°C, 37°C or 60°C 
and the encapsulation of verapamil and prochiorperazine 
was determined after removal of unentrapped rug by 
column chromatography. Aliquots of 0.1 ml of liposomes 
were centrifuged on a 1 ml mini-column of Sephadex G-50 
that was pre-equilibrated in HBS. Lipid and verapamil 
content were measured by liquid scintillation counting 
(LSC) and prochlorperazine content was measured by dis- 
solving an aliquot of the liposomes in ethanol and measur- 
ing absorbance at314 nm. 
After drug uptake, the leakage of the entrapped rug 
was determined by dialysis. Specifically, liposomes with 
uptake efficiencies > 90% were transferred irectly to 
dialysis tubing. Preparations with entrapment efficiencies 
< 90% were subjected to column chromatography to re- 
move the non-encapsulated drug prior to dialysis. All 
samples were dialyzed against 1000 volumes of HBS at 
37°C. At various times, aliquots were removed and as- 
sayed for lipid and for the amount of drug remaining 
encapsulated as described above. The data presented are 
from side-by-side comparisons. The relationship between 
the different samples was very consistent between different 
experiments, even though the absolute flux rates were 
somewhat more variable. 
2.5. Calculation of permeabili O, coefficients 
Permeability coefficients (P, cm/s)  were calculated as 
described previously [14] using: 
P = J / (a .  AC) 
where J is the flux (/~mol s-~), AC is the concentra- 
tion gradient of the drug (/.tmol cm -3) and A is the total 
surface area of the liposomes (cm2). The flux was obtained 
from the initial slope of the drug efflux curves (Fig. 2A 
and Fig. 3A) over which the variation of drug content vs. 
time was linear ( r2> 0.98). The concentration gradient 
was calculated from the known average vesicle diameter 
obtained from the QELS data and from the initial 
drug/lipid ratio. Membrane surface area (A) was calcu- 
lated from the lipid concentration a d assuming an average 
lipid molecular area of 0.5 nm 2. 
For the purposes of calculating the permeability coeffi- 
cients for the neutral forms of the drugs, the starting 
assumption that the drug efflux observed at pH i = 4.0 was 
due exclusively to the neutral form of the drug used. The 
intraliposomal concentration of the neutral species was 
obtained from the pK~ values of 6.8 and 8.1 for verapamil 
and prochlorperazine, respectively (data not shown) and 
the initial drug/lipid ratio of the liposomes after drug 
uptake. Therefore, at pH i --- 4.0, the ratio of neutral/proto- 
nated forms of the total intraliposomal verapamil and 
prochlorperazine were <5.  10-3:1 and 5. 10-4:1, re- 
spectively. To obtain the permeability coefficient for the 
charged species of the drugs, the permeability coefficients 
calculated for the neutral forms of the drugs (i.e., the P 
value calculated at pH i = 4.0) were used to estimate the 
proportion of the total flux observed at pH~ = 2.0 that was 
due to the neutral form of the drug. This flux was sub- 
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tracted from the total flux that was observed at pH~ = 2.0, 
and the flux remaining at pH i = 2.0 was taken to be due to 
the charged forms of the drugs. The permeability coeffi- 
cients for the charged drugs were then calculated as de- 
scribed above using the corrected concentration gradients 
for the charged forms of verapamil and prochlorperazine. 
The presented results are those obtained using this calcula- 
tion procedure, however, it should be noted that very 
similar permeability coefficients were obtained for the 
neutral and charged forms of the drugs when the calcula- 
tion was initiated with the assumption that all of the flux 
observed at pH i = 2.0 was due exclusively to the charged 
species. First-order rate constants, k, for drug leakage were 
calculated from the slope ( -  k) of the In (% drug remain- 
ing) vs. time plots and the half-lives (Tl/2) obtained using 
T1/2 = 0.693/k. 
3. Resu l ts  
3.1. pH gradient-mediated drug uptake 
The uptake of verapamil and prochlorperazine into large 
unilamellar vesicles composed of DSPC/cholesterol or 
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Fig. 2. Release of verapamil from large unilamellar liposomes composed 
o f  DSPC/cho les tero l  (55 :45 ,  mo l /mo l )  and  
DSPC/cholesterol/stearylamine (50:40:10, mol/mol) during dialysis at 
37°C. Curves represent data for DSPC/cholesterol (O ,O)  and 
DSPC/cholesterol/stearylamine (12, I1) with intraliposomal pH of 4.0 
(O, II ) or 2.0 (O,D).  Curves represent the % of initial verapamil (A) 
and the In of the % of veraparnil remaining (B). The standard eviations 
for these samples were typically < 4%. Linear regressions of the lines 
presented in (B) had r 2 values at least 0.98 and the slopes were used for 
calculation of TI/2 values. 
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Fig. 3. Release of prochlorperazine from large unilamellar liposomes 
composed of DSPC/cho les tero l  (55:45, mo l /mo l )  and 
DSPC/cholesterol/stearylamine (50:40:10, mol/mol) during dialysis at 
37°C. Curves represent data for DSPC/cholesterol (0 ,0 )  and 
DSPC/cholesterol/stearylamine (D,I1) with intraliposomal pH of 4.0 
(O, I1 ) or 2.0 (O,I:]). Curves represent the % of initial prochlorperazine 
(A) and the In of the % of prochlorperazine remaining (B). The standard 
deviations for these samples were typically < 4%. Linear regressions of 
the lines presented in (B) had r 2 values at least 0.94 and the slopes were 
used for calculation of Ti/2 values. 
DSPC/cholesterol/stearylamine is summarized in Table 
1. Drug uptake reached their maximum values within one 
minute of drug addition and were stable during uptake 
periods as long as 30 rain (data not shown). The efficiency 
of entrapment of verapamil in DSPC/cholesterol lipo- 
somes with a pH i = 4.0 was 60-65% at 21°C, 37°C and 
60°C. Encapsulation efficiency improved to 85% to 89% 
when the pH~ was 2.0. The presence of 10 mol% stearyl- 
Table 1 
Summary of the uptake efficiency of verapamil and prochlorperazine into 
l iposomes of either DSPC/cho les tero l  (DSPC/Cho l )  or 
DSPC/cholesterol/stearylamine (DSPC/Chol/SA) with a pH i of either 
2.0 or 4.0 
Lipid pH i Drug uptake (%) 
verapamil prochlorperazine 
21 °C 37°C 60°C 21 °C 60°C 
DSPC/Chol 4.0 59.5 64.5 67.8 96.5 92.0 
DSPC/Chol 2.0 84.8 82.4 88.7 100 - 
DSPC/Chol/SA 4.0 - - 63.8 100 - 
DSPC/Chol/SA 2.0 - - 80.8 100 - 
All liposomes had an average diameter of approx. 130 nm and pH 0 = 
7.3-7.6. Uptake of 100% represents drug/lipid (mol/mol) ratios of 
0.185 and 0,133 for verapamil and prochlorperazine, r spectively. 
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amine in the vesicles did not improve the encapsulation 
efficiency (Table 1). In contrast to verapamil, the encapsu- 
lation of prochlorperazine into both DSPC/cholesterol and 
DSPC/cholesterol/stearylamine liposomes occurred at ef- 
ficiencies of 95-100% under milder conditions than for 
verapamil. That is, encapsulation efficiencies for prochlor- 
perazine were approx. 100% at 21°C and pH i = 4.0 (Table 
1). The loading of both verapamil and prochlorperazine 
into liposomes was dependent on the presence of a pH 
gradient; i.e., no uptake was observed in liposomes with 
pH i = pH o = 4.0 (data not shown). 
The magnitude of the transmembrane pH gradients has 
been evaluated using [14C]methylamine. Prior to drug up- 
take, transmembrane pH gradients of 3.1 to 3.4 pH units 
were measured for both DSPC/cholesterol and 
DSPC/cholesterol/stearylamine l posomes dispersed at 
pH 4.0, corresponding to calculated intraliposomal pH 
values of 4.0 to 4.4. In those liposomes dispersed in citrate 
buffer at pH 2.0, the magnitude of the pH gradient (ap- 
prox. 5 units) was greater than that which can be reliably 
determined using methylamine (approx. 3.8 units [15]). For 
these systems in buffer at pH 2.0, we typically measured 
transmembrane pH gradients of approx. 3.8 pH units, 
consistent with the presence of a pH gradient of approx. 5 
units. 
3.2. Drug leakage 
The leakage of verapamil from DSPC/cholesterol and 
DSPC/cholesterol/stearylamine liposomes during dialysis 
at 37°C as a function of intraliposomal pH is shown in Fig. 
2A. Verapamil leakage followed first order kinetics under 
all experimental conditions used here as shown by the 
linear relationship between the In of intraliposomal vera- 
pamil vs. time (Fig. 2B). At a pH i = 4.0, verapamil effiux 
from DSPC/cholesterol liposomes resulted in the loss of 
50% of the entrapped drug (TI/2) after 3.7 h. The presence 
of 10 mo1% stearylamine in DSPC/cholesterol liposomes 
with pH~ = 4.0 had no influence on the leakage kinetics of 
verapamil; the T1/2 for release was 4.0 h. The retention of 
verapamil in DSPC/cholesterol liposomes with a larger 
pH gradient (pH i = 2.0) improved the 7"1/2 for leakage 
from 3.7 h at pH~ = 4.0 to 14.5 h with pH i = 2.0. The 
retention of verapamil in DSPC/cholesterol liposomes 
with pH i = 2.0 was significantly improved (TI/2 = 73.4 h) 
by the presence of I0 mol% of stearylamine. 
The leakage of prochlorperazine from liposomes com- 
posed of DSPC/cholesterol or DSPC/cholesterol/ 
stearylamine is shown in Fig. 3A. As observed for the 
leakage of verapamil, first order efflux kinetics were ob- 
served for the release of prochlorperazine from these lipo- 
somes (Fig. 3B). Prochlorperazine was slightly less perme- 
able than verapamil. Release of prochlorperazine from 
large unilamellar liposomes composed of DSPC/  
cholesterol with pH i = 4.0 occurred with a Tj/2 of 8.1 h, 
compared to 3.7 h for verapamil eakage from identical 
Table 2 
Permeability coefficients (P) for the leakage of verapamil and prochlor- 
perazine from liposomes of DSPC/cholesterol (DSPC/Chol) or 
DSPC/cholesterol/stearylamine (DSPC/Chol/SA) 
Lipid P (cm/s) 
verapamil prochlorperazine 
neutral cationic neutral cationic 
DSPC/Chol 1.2-10 s 5.5.10- 12 8.3.10-8 1.2.10-12 
DSPC/Cho l /SA 6.2.10 9 3.1.10 13 7.8.10-8 5.7.10-f~ 
Permeability coefficients for the neutral and cationic fbrms of verapamil 
and prochlorperazine were calculated as described in the Materials and 
methods. 
liposomes. The presence of 10 mol% stearylamine in the 
DSPC/cholesterol liposomes with a pH~ = 4.0 did not 
substantially improve the retention of prochlorperazine 
(7"i/2 = 10.8 h). Increasing the magnitude of the trans- 
membrane pH gradient, effected by a decrease of the 
intraliposomal pH to 2.0, significantly improved the reten- 
tion of prochlorperazine in DSPC/cholesterol liposomes 
(TI/2 =22.2 h). The efflux of prochlorperazine from 
DSPC/cholesterol liposomes with pH~ = 2.0 was further 
reduced by the presence of 10 mol% stearylamine (T~/2 
increased to 36.0 h), representing a 4.5-fold improvement 
over the results obtained at pH~ = 4.0. 
Previous tudies have suggested that drug encapsulation 
and release properties could be explained entirely on the 
basis of the permeation of the neutral form of the drug [5]. 
If this were also the case with verapamil and prochlorpera- 
zine, then the presence of a cationic lipid in the membrane 
would not be expected to affect drug release, since there 
should be negligible effect of a surface charge on neutral 
drugs. However, the data presented in Figs. 2 and 3 clearly 
indicate a pH-dependent effect of the cationic lipid on drug 
permeability. To further investigate the effect of intralipo- 
somal pH and the presence of stearylamine on drug re- 
lease, the permeability coefficients of the neutral and 
cationic forms of verapamil and prochlorperazine (Table 2) 
have been calculated from the drug efflux curves (Fig. 2A 
and Fig. 3A). For the neutral form of verapamil, the 
permeability coefficient in DSPC/cholesterol liposomes 
(1.2 • 10-s  cm/s )  was similar to that in 
DSPC/cholesterol/stearylamine liposomes (0.62 • 10-8 
cm/s; Table 2). In contrast, the permeability coefficient 
for the charged form of verapamil was decreased by more 
than an order of magnitude in the presence of stearylamine 
(5.5. 10 -12 vs. 3.1 - 10 13 cm/s; Table 2), In liposomes 
composed of either DSPC/cho lestero l  or of 
DSPC/cholesterol/stearylamine, the permeability coeffi- 
cients for the neutral form of verapamil were 10 3- tO 
104-fold greater than those for the cationic form of vera- 
pamil. Results similar to those observed for verapamil 
were also obtained for prochlorperazine. The permeability 
coefficient for the neutral form of prochlorperazine in 
DSPC/cholesterol liposomes (8.3. 10 -8 cm/s)  was very 
similar to that obtained in DSPC/cholesterol/stearyla- 
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mine liposomes (7.8 • 10 -8 cm/s,  Table 2). However, the 
permeability coefficient for the charged species of 
prochlorperazine was decreased by the presence of stearyl- 
amine (Table 2). In both liposome types, the calculated 
permeability coefficients for the neutral form of prochlor- 
perazine were approx. 105-fold higher than for the cationic 
form of the drug. Overall, the presence of 10 moi% 
stearylamine in DSPC/cholesterol liposomes had no effect 
on the calculated permeability coefficients for the neutral 
forms of either verapamil or prochlorperazine, but signifi- 
cantly reduced the permeability coefficients for the charged 
forms of both drugs. For both verapamil and prochlorpera- 
zine, the neutral drug was 10 3 to 10 5 orders of magnitude 
more permeable than was the cationic form of the drug. 
To account for the possibility that the pH gradients 
were partially collapsed uring drug uptake, we have also 
calculated the permeability coefficients for the charged and 
neutral species of verapamil and prochlorperazine under 
conditions where the transmembrane pH gradient had col- 
lapsed by 2-3 pH units. Specifically, it was assumed that 
the pH 2.0 systems had collapsed to an intraliposomal pH 
of 5.0 and that the pH 4.0 systems had collapsed to an 
intraliposomal pH of 6.0. Using these assumptions, the 
calculated permeability coefficients for the charged forms 
of verapamil and prochlorperazine were in the range of 
10 -12 to l0  -14 cm/s  and were decreased by approxi- 
mately one order of magnitude by the presence of stearyl- 
amine whereas the permeability coefficients calculated for 
the neutral forms were not affected by the presence of 
stearylamine (data not shown). Consequently, significant 
collapse of the transmembrane pH gradient did not affect 
the qualitative relationship between the neutral and charged 
species reported in Table 2. 
3.3. A mathematical model for  drug release kinetics 
In order to achieve a better understanding of the factors 
that contribute to the permeability of neutral and cationic 
forms of verapamil and prochlorperazine, we have devel- 
oped a mathematical model for the kinetics of drug release 
from liposomes. This model described the passive diffu- 
sion of both the charged and neutral forms of the drug 
from the liposome and incorporates the effects of intralipo- 
somal pH, surface charge of the inner monolayer of the 
liposomes, charge on the permeating drug and the effect of 
intraliposomal citrate buffer on both surface charge and 
drug leakage. 
The change in the number of molecules of the neutral 
form of the drug on the interior of the liposome, Ai, over 
time can be denoted as dNAJdt  where N = number and 
dt = the change in time, t. According to Fick's Law: 
dNA i 
dt " = k ( [A]° -  [A]i) 
where k = the rate constant, [A] 0 = the concentration of 
the neutral form on the outside of the liposome and 
[A]i = the concentration f the neutral form of the drug on 
the inside of the liposome. Similarly: 
dNA o 
dt k ( [A] i -  [A]°) 
dUa + 
dt k ( [a+ ]° -  [A+]i) 
dNA~ 
at -k ( [A  +] i - [  A+]0) 
where [A+]i and [A+]0 represent the concentration of the 
charged form on the inside and outside of the liposome, 
respectively. If [A] 0 and [A+]0 are kept effectively at zero 
by removing free drug from the outside of the liposome, 
then the flux equations are further simplified: 
dNAi =(d[A l i ]  = 
dt ~~~t ] -k[A] i  (1) 
dNA + ( d[A + ]i 
dt ~ ---d-~ ] = -k[A+] i  (2) 
The concentrations of A and A + at the intraliposomal 
membrane surface ([A]i(0) and [A+]i(0), respectively) are; 
d[A]i(O) 
k[A]i (3) 
dt 
d[A+ ]i(O) 
k[A+]i (4) 
dt 
However, since the surface charge should have no effect 
on the neutral form of the drug, Eqs. (1) and (3) are 
identical. 
A positively charged membrane exerts a repulsive lec- 
trostatic force on positively charged solutes such that the 
concentration of these molecules is lowest at the mem- 
brane surface and increases exponentially with increasing 
distance from the membrane surface according to [16]; 
where [A + ] = the bulk concentration of the charged form 
of the drug, e- - the charge of an electron (1.602. l0  -19 
Coulombs), K- - the Boltzmann constant (1.380. l0  -23 J 
K-~), T = temperature in Kelvin and 00 = the membrane 
surface potential in V. 
The membrane surface potential is related to the surface 
charge density, o', by the equation [16]: 
~r = 27----2 XCiexp KT - 1 (6) 
where C i = the concentration f the ith species of molecule 
in solution and zi = the valence of the ith charged species 
of molecule in solution. The surface charge density is the 
percentage of the charged lipid in the membrane divided 
by the surface area it occupies. A lipid carrying one 
positive charge at a concentration f l0 mol% and occupy- 
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ing an average lipid surface area of 60 ~2 would give a 
surface charge density of 0.1/60 = 0.00167 charges ,&- 2. 
Therefore, any ions in solution will alter the membrane 
surface potential when the surface charge density is held 
constant (Eq. (6)). When C i in Eq. (6) is substituted by 
any ionic forms of the citrate buffer, the charged form of 
the drug and ionic forms of salt present in solution, then 
Eq. (6) becomes: 
{ 1 [B ] exp - 1 o" = 27---2 - -~  
+ [B2-] (exp( -~) -1 )  
+ [B3- ] (exp(~T°  ) - 1 ) 
+ [A+ ] (exp( -eO°  
- -  e l~0 
+ [C + ] (exp( -~- - )  -1  ) 
+Ic-l(ex (  t-1  (7) 
where 
[B-] 
[B 2- ] 
k I [B ]  t° '  
[H + ] f(H +) 
k lk  2 [B]  t°t 
[H+] 2 f (H  + ) 
k]k2k 3 [B] t°t 
[ B3 ] [H ÷]3/(H +) 
and where 
f (H+)  = 1 + ~- -~ + - -  
klk2 klk2k3 ] 
[n+] + t--ff J 
Here, [B-],[B 2- ],[B 3-  ] --- the charged species of the buffer, 
k j, k 2, k 3 = the dissociation constants of the buffer, [B] t°t 
= the total buffer concentration i solution, [C +] = the 
concentration of singly positively charged ions in solution 
necessary for charge balance, [C-] = the concentration of
singly negatively charged ions in solution necessary for 
charge balance. 
The membrane surface potential was determined from 
Eq. (6) by iteration at each time increment, dt. To calcu- 
late the intraliposomal concentrations of neutral and 
charged forms of the drug, Eqs. (3), (4), (5) and (7) were 
solved at each time increment dt. In order to facilitate this 
calculation, we have used an intraliposomal buffer concen- 
tration of 0.3 M and three pK a values of 3.1, 4.8 and 6.4 
(= kl,k2,k3). We have modeled the release of a cationic 
drug with a single charge and a pK a = 9.0, whose total 
intraliposomal concentration after loading was 180 mM 
0.18' 
l.U 
o.14 
0 - - .% 
¢~ 0.10 L J "" 
50 1 O0 180 200 250 
Time (sec) 
Fig. 4. Mathematical model of the effect intraliposomal pH and the effect 
of a 10% surface charge density on the efflux of a drug with pK~ = 9 
from large unilamellar liposomes during dialysis. Curves represent drug 
leakage from liposomes with intraliposomal pH of 4.0 (0,  • ) or 2.0 
(O,t3) in the absence (0 ,0 )  and presence (13,•)  of a 10% positive 
surface charge density. 
and whose concentration utside the liposome was negligi- 
ble. The release of this drug was modeled using the 
assumption that the intraliposomal pH values (2.0 and 4.0) 
were not altered by drug loading. However, we have also 
calculated the extent of collapse of the transmembrane pH
gradient hat is expected to occur due to drug uptake and 
have also modeled the drug release kinetics using the 
resultant intraliposomal pH values. Under these conditions, 
the rates of drug release had the same qualitative relation- 
ships between liposomes as a function of intraliposomal 
pH and surface charge, but the absolute rates were mod- 
estly different from those obtained if it was assumed that 
the intraliposomal pH was not altered by drug loading. 
The results of the mathematical modeling of drug efflux 
kinetics, as affected by intraliposomal pH and the presence 
of a surface charge density, are shown in Fig. 4. With an 
intraliposomal pH of 4.0, the presence of 10 mol% steary- 
lamine did not affect the retention of the drug within the 
liposomes. Since citrate has a pK at 3.1, at pH 4.0 a large 
amount of the citrate buffer is in the monovalent anion 
form and effectively neutralizes the positive membrane 
surface potential. Consequently, there is very little effect 
of a surface charge on the rate of efflux at pH 4.0; 
calculated half-lives for drug leakage at pH 4.0 were 
within 7% of each other in the presence and absence of 10 
mol% stearylamine (Fig. 4). In contrast, at pH 2.0, most of 
the citrate is uncharged and does not screen the positive 
membrane surface charges. Therefore, a significant mem- 
brane surface potential will exist in the presence of a 
positive surface charge density. It is obvious that when the 
membrane surface potential is high, [A+](0) is lower than 
when no surface potential is present. Therefore, in the 
presence of a membrane surface potential the effective 
transmembrane concentration gradient of the drug A + is 
lower and the rate of efflux is expected to be slower. In 
this model, there was a 6.3-fold increase in the half-life of 
drug leakage when the intraliposomal pH was decreased 
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from 4.0 to 2.0 in the absence of stearylamine (Fig. 4). 
With the further addition of 10 tool% stearylamine at an 
intraliposomal pH of 2.0, the calculated half-life for drug 
leakage increased by an additional 2.3-fold (Fig. 4). Over- 
all, the modeled rug retention was improved by 14.7-fold 
when the liposomes were changed from uncharged lipo- 
somes at pH 4.0 to liposomes possessing a 10 tool% 
surface charge at pH 2.0. This compares favorably to the 
observed increases in drug retention of 19.8-fold for vera- 
pamil and 4.5-fold for prochlorperazine in the comparable 
liposomal systems. 
4. Discussion 
The therapeutic activity of many liposomal formulations 
of membrane-permeant drugs will likely depend on the 
success of efforts to design liposomes having enhanced 
drug retention characteristics. Previous tudies with liposo- 
mal vincristine have indicated that antitumor activity can 
be significantly improved by using liposomes with en- 
hanced rug retention characteristics [ 17]. The rationale for 
the experiments described here was that the permeability 
of cationic drugs could be significantly reduced if the inner 
monolayer of the liposome possessed a positive surface 
potential. In these experiments, the surface charge on the 
inside monolayer was created by the presence of the 
cationic lipid stearylamine since it is known to redistribute 
to the inner monolayer of liposomes in the presence of a 
transmembrane pH gradient with the inside acidic (inside 
acidic) [10,11]. 
The results presented in this paper confirm the predic- 
tion that drug permeability could be significantly reduced 
if the inner monolayer of the liposome possessed a positive 
surface charge. In the presence of 10 mol% stearylamine at
pH i = 2.0, the leakage of both verapamil (Fig. 2A) and 
prochlorperazine (Fig. 3A) was significantly reduced. This 
was observed in the empirical results as increased T~/2 
values for drug release (Fig. 2A and Fig. 3A) and as 
decreased permeability coefficients in the presence of 10 
mol% stearylamine atpH i = 2.0 (Table 2) calculated from 
the efflux curves. It is likely that the reduced rug leakage 
observed in the presence of stearylamine atpH i = 2.0 was 
primarily a consequence of the 10-fold reduction of the 
permeability coefficients for the charged forms of both 
verapamil and prochlorperazine (Table 2). If the neutral 
form of the drug is the only form that will cross the 
membrane, then the presence of a membrane surface charge 
should have negligible ffect on drug effiux. However, if a 
positive membrane surface potential affects the rate of 
efflux, then it must be assumed that the protonated form of 
the drug contributes significantly to drug permeation, since 
neutral molecules are unaffected by membrane surface 
charge. 
While the surface charge density on the inner mono- 
layer of the liposomes has not been explicitly measured, it
should be noted that the observed effiux of both verapamil 
and prochlorperazine could be accurately modeled by as- 
suming that a surface potential developed as a conse- 
quence of stearylamine r distribution to the inner mono- 
layer of the liposome. In this model, the leakage of drug is 
directly proportional to the concentration f the drug at the 
membrane surface. Therefore, charge repulsion due to the 
presence of stearylamine effected a reduction of the local 
concentration of verapamil and prochlorperazine adjacent 
to the membrane surface, effectively reducing their con- 
centration gradients across the membrane. It should be 
added that the absence of an effect of stearylamine on drag 
leakage at pH i = 4.0 is also accounted for by this analysis. 
Since citric acid has a pK at 3.1, at pH~ = 4.0 there is a 
significant concentration f anionic citrate within the lipo- 
some which screens the positive surface charges due to 
stearylamine and, consequently, reduces the surface charge 
density and membrane potential to negligible levels. In 
contrast, at pH~ = 2.0 the anionic citrate concentration is 
lower than that necessary to neutralize the positive surface 
potential due to stearylamine. The positive surface poten- 
tial effectively prevents the close approach of the charged 
drugs to the membrane surface via long-range lectrostatic 
repulsion. This results in both a reduction of the effective 
drug concentration gradient across the membrane and a 
reduction of drug partitioning into the bilayer. As an 
alternative xplanation for the absence of an effect of 
stearylamine on drug leakage at pH~ = 4.0, it is possible 
that the predominant species permeating the bilayer was 
the neutral forms of verapamil and prochlorperazine, as
was assumed for the calculation of the permeability coeffi- 
cient. The neutral forms of these drugs would not be 
affected by the presence of stearylamine, as was observed 
(Figs. 2 and 3). 
The results presented here indicate that both the charged 
and the neutral species of the drugs verapamil and 
prochlorperazine are membrane permeable. However, the 
uncharged forms of these drugs are approximately four 
orders of magnitude more permeable than are the charged 
forms (Table 2). A consequence of this difference in 
permeability coefficients is that the total flux of drug at 
pH i = 4.0 is dominated by flux due to the neutral species 
of the drug, despite the fact that the protonated drug is the 
predominant form at this pH. Similarly, at pH~ = 2.0 the 
neutral form of verapamil represented only 0.0005% of the 
intraliposomal drug but accounted for 1.1% of the flux of 
the drug from DSPC/cholesterol liposomes and 9.2% of 
the flux from DSPC/cholesterol/stearylamine liposomes. 
At pH i = 2.0 the neutral form of prochlorperazine r pre- 
sented 0.00005% of the total drug, but accounted for 3.4% 
of the flux from DSPC/cholesterol liposomes and 6.4% of 
the flux from DSPC/cholesterol/stearylamine liposomes. 
While it may be considered a surprise that the charged 
forms of verapamil and prochlorperazine are membrane 
permeable, it is notable that the permeability coefficients 
for the protonated forms of these drugs, approx. 10 -12 
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cm/s in DSPC/cholesterol liposomes, are comparable to 
those measured previously at 10 -~2 to 10 -14 cm/s  for 
cations such as Na ÷ and K + [18]. The difference in 
molecular size of verapamil and prochlorperazine, com- 
pared to Na + and K +, suggests that the charge on the 
compound is an important determinant of the permeation 
rate, a conclusion that is consistent with the effect of 
stearylamine on the permeability coefficients. In addition, 
the uptake of a positively charged analogue of dibucaine 
(N-methyldibucaine) in response to a membrane potential 
[19] supports our conclusion that cationic drugs are mem- 
brane-permeable. 
Our experience with both DSPC/cholesterol and 
DSPC/cholesterol/stearylamine liposomes indicates that 
they are present as a highly ordered liquid-crystalline 
phase. This is consistent with published results by other 
groups showing that similar DSPC/cholesterol mixtures 
have no detectable phase transition between 35°C and 
70°C [20]. Further, the presence of 10 mol% stearylamine 
in egg PC liposomes had no effect on either the magnitude 
of the transmembrane pH gradient or liposome size [10]. 
Both characteristics are reliable indicators of the structural 
integrity of the liposomes. To evaluate the effect of drug 
encapsulation on bilayer structure, we have used the pub- 
lished octanol/water partition coefficient for prochlorpera- 
zine hydrochloride [21 ] to estimate the amount of prochlor- 
perazine that would be present in the lipid bilayer after 
drug loading. At maximum levels of encapsulation, the 
intraliposomal concentration of prochlorperazine was ap- 
prox. 180 raM. In 120 nm diameter liposomes, the amount 
of neutral prochlorperazine partitioning into the lipid bi- 
layer would represent approx. 3.2 tool% of the total lipid. 
However, at intraliposomal pH values of 4.0 and 2.0, the 
drug is predominantly in the charged form. Therefore, 
intraliposomal concentrations of neutral prochlorperazine 
would be < 0.01 mM and the proportion of neutral 
prochlorperazine in the lipid bilayer would be <0.01 
mol%. Further, due to the charge present on the intralipo- 
somal prochlorperazine after drug loading, and because the 
partition coefficient for the charged from is expected to be 
significantly lower than that for the neutral form, it is 
likely that the partitioning of intraliposomal prochlorpera- 
zine (predominantly the charged form) into the bilayer is 
very low. Although a partition coefficient is not available 
for verapamil, its similarity with the structure and solubil- 
ity of prochlorperazine suggests that it would not be 
significantly different from prochlorperazine in its parti- 
tioning into the hydrophobic phase of the bilayer. We 
conclude, therefore, that the bilayer partitioning of these 
drugs is negligible and that they have no significant impact 
on the physical state of the bilayers. 
In summary, we have demonstrated that the retention of 
cationic drugs within liposomes can be significantly im- 
proved when the liposomes contain the cationic lipid 
stearylamine and a transmembrane pH gradient utilizing a 
low entrapped pH. In principle, this approach is applicable 
to a wide variety of cationic drugs and may significantly 
improve the therapeutic activity of liposomal drug formu- 
lations. 
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